Transcatheter aortic valve replacement has transformed the management of severe aortic stenosis across diverse surgical risk profiles. However, post-procedural imaging frequently identifies subclinical leaflet thickening on multidetector computed tomography. This phenomenon, clinically recognized as hypoattenuated leaflet thickening, raises substantial concerns regarding long-term bioprosthetic valve durability and thromboembolic risk. Consequently, clinicians have debated whether temporary oral anticoagulation can safely suppress thrombus formation without exposing patients to excessive bleeding hazards. The NOTION-4 trial directly addressed this clinical dilemma by evaluating whether a three-month course of direct oral anticoagulant therapy yields lasting protection compared with standard antiplatelet therapy.

Pathophysiology of Subclinical Leaflet Thickening in Transcatheter Bioprostheses

Hypoattenuated leaflet thickening represents a distinctive form of subclinical leaflet thrombosis that occurs on transcatheter heart valve leaflets. Mechanistically, altered local hemodynamics, blood stasis within the neo-sinus, and surface-induced thrombogenicity contribute to early thrombus deposition. Although many patients remain entirely asymptomatic, severe leaflet thickening may lead to reduced leaflet motion and elevated transvalvular gradients. Furthermore, observational studies have linked subclinical thrombosis to an increased hazard of transient ischemic attacks and cerebral infarction. Therefore, identifying an optimal antithrombotic strategy represents a paramount goal in structural interventional cardiology. Historically, clinicians routinely prescribed dual antiplatelet therapy or empiric anticoagulation to mitigate these early post-implantation risks. However, extensive clinical trials demonstrated that dual antiplatelet therapy significantly increases major bleeding without reducing thromboembolic events. Consequently, international guidelines currently recommend single antiplatelet therapy as the default standard of care for patients without established indications for chronic oral anticoagulation. Nonetheless, whether a brief, targeted course of direct oral anticoagulants could safely eliminate early leaflet thickening and establish durable valve function remained an open question before the NOTION-4 trial.

The NOTION-4 Trial Design and Experimental Strategy

The Nordic Aortic Valve Intervention 4 trial was designed as a prospective, randomized controlled trial. Specifically, investigators enrolled patients who underwent successful transcatheter aortic valve implantation and had no preexisting indication for long-term oral anticoagulation. The study randomized 352 patients in a 1:1 ratio across participating cardiovascular centers. Following exclusions for screening failures and consent withdrawals, researchers analyzed 176 patients assigned to lifelong single antiplatelet therapy and 171 patients assigned to three months of direct oral anticoagulant therapy followed by lifelong single antiplatelet therapy. The primary endpoint evaluated the overall prevalence of hypoattenuated leaflet thickening on four-dimensional cardiac computed tomography at twelve months post-procedure. Additionally, the protocol incorporated mandatory serial computed tomography imaging at three months to characterize early leaflet dynamics. Clinicians evaluated secondary clinical outcomes, including all-cause mortality, ischemic stroke, and major or life-threatening bleeding complications. Ultimately, this rigorous trial design aimed to determine whether early pharmacological suppression of thrombosis translates into sustained anatomical and clinical benefits over time.

Primary Imaging Outcomes: Transient Protection Without Long-Term Efficacy

The imaging findings from the NOTION-4 trial provided critical insights into the temporal behavior of prosthetic valve thrombosis. At three months post-procedure, cardiac computed tomography revealed hypoattenuated leaflet thickening in 31.8% of patients receiving single antiplatelet therapy compared with only 12.1% of patients receiving three months of direct oral anticoagulant therapy. Therefore, active direct oral anticoagulation demonstrated potent early efficacy in suppressing leaflet thrombus formation during the treatment window. However, this protective anatomical effect dissipated rapidly after the cessation of oral anticoagulants. At the primary twelve-month endpoint, computed tomography scans demonstrated hypoattenuated leaflet thickening in 32.2% of patients in the single antiplatelet group and 28.3% in the direct oral anticoagulant group. The resulting risk difference of -3.9% was not statistically significant. Consequently, serial imaging proved that short-term direct oral anticoagulant therapy does not prevent delayed or recurrent leaflet thickening once discontinued. These definitive observations demonstrate that early thrombus inhibition does not induce permanent resistance to flow-mediated prosthetic leaflet thickening.

Clinical Safety Endpoints and the Hazard of Post-TAVR Anticoagulation

In addition to imaging efficacy, the NOTION-4 trial rigorously assessed clinical safety endpoints across both treatment cohorts. At twelve months, the composite endpoint of all-cause mortality, stroke, or major and life-threatening bleeding occurred in 2.3% of patients in the single antiplatelet therapy group. In stark contrast, 8.2% of patients in the three-month direct oral anticoagulant group experienced this adverse composite outcome. This difference corresponded to a statistically significant risk increase of 5.9%. Notably, the elevated event rate in the anticoagulant cohort was driven primarily by excess major bleeding complications and numerically higher mortality. Furthermore, direct oral anticoagulation failed to provide any measurable reduction in ischemic cerebrovascular events during the one-year follow-up period. These clinical findings align closely with preceding randomized trials, such as the GALILEO and ADAPT-TAVR studies, which also identified unfavorable safety profiles with routine anticoagulation. Thus, the pharmacological prevention of subclinical imaging abnormalities does not compensate for the tangible clinical risks associated with systemic anticoagulation.

Translating NOTION-4 Evidence into Contemporary Clinical Practice

The findings of the NOTION-4 trial carry vital clinical implications for cardiologists, structural heart specialists, and general physicians managing post-TAVR patients. Firstly, the trial firmly reinforces contemporary professional guidelines recommending against routine direct oral anticoagulants in patients without baseline anticoagulation indications. Lifelong single antiplatelet therapy remains the safest, most effective standard of care because it minimizes hemorrhagic complications while delivering favorable clinical outcomes. Secondly, clinicians should avoid routine computed tomography surveillance for subclinical leaflet thickening in asymptomatic individuals. Because subclinical thickening dynamically waxes and wanes without directly predicting immediate catastrophic valve failure, treating radiographic findings alone frequently causes unintended harm. Nevertheless, if a patient develops symptomatic valve dysfunction, unexplained transvalvular gradient escalation, or overt thromboembolism, targeted anticoagulant therapy remains biologically justified and clinically effective. Ultimately, NOTION-4 highlights the importance of prioritizing hard clinical outcomes, such as survival and major bleeding avoidance, over surrogate imaging endpoints in structural cardiovascular medicine.

Frequently Asked Questions (FAQs)

What is subclinical leaflet thickening, and how is it diagnosed after TAVR?

Subclinical leaflet thickening refers to the formation of microscopic thrombi on prosthetic valve leaflets, visualized on cardiac computed tomography as hypoattenuated leaflet thickening. It often occurs without noticeable symptoms or significant hemodynamic compromise. Physicians diagnose this condition primarily using high-resolution four-dimensional multidetector computed tomography scans, which evaluate leaflet thickness and detect any associated reduction in leaflet motion during the cardiac cycle.

Why did the NOTION-4 trial show no lasting benefit from short-term DOAC therapy?

The NOTION-4 trial showed that direct oral anticoagulants effectively suppress thrombus deposition while actively administered during the first three months. However, when patients discontinued the anticoagulant, altered blood flow and local hemodynamics around the bioprosthesis allowed thrombosis to recur. By twelve months, leaflet thickening rates in the DOAC cohort rebounded to levels comparable with standard single antiplatelet therapy, confirming the lack of sustained benefit.

What is the recommended antithrombotic strategy for post-TAVR patients without atrial fibrillation?

Current cardiology guidelines recommend lifelong single antiplatelet therapy, typically with low-dose aspirin, for post-TAVR patients who lack baseline indications for oral anticoagulation. Evidence from NOTION-4 and previous randomized trials confirms that adding direct oral anticoagulants increases major bleeding risks without improving survival or stroke prevention. Therefore, routine empiric anticoagulation is contraindicated unless an explicit indication, such as atrial fibrillation or venous thromboembolism, develops.

Disclaimer: This content is for informational and educational purposes only, and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals should exercise their independent clinical judgment when managing individual patients. Refer to the latest local and national guidelines for clinical practice.

References

1. Jørgensen TH et al. Short-Term Anticoagulant Therapy and Subclinical Leaflet Thickening in Transcatheter Aortic Valves: The NOTION-4 Trial. J Am Coll Cardiol. 2026 Aug 30. doi: undefined. PMID: 42669071.
2. De Backer O, Jørgensen TH, Bieliauskas G, et al. Prospective study on the impact of different antithrombotic therapies on subclinical leaflet thickening and its temporal dynamics in transcatheter aortic valves—The NOTION-4 trial. Am Heart J. 2025;279:1-8.
3. Montalto C, Mangieri A, Spagnolo M, et al. Subclinical Leaflet Thrombosis After Transcatheter Aortic Valve Replacement: A Meta-Analysis. JACC Cardiovasc Interv. 2021;14(24):2699-2709.
4. Dangas GD, Tijssen JGP, Wöhrle J, et al. A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. N Engl J Med. 2020;382(2):120-129.